Background: The side effects of glucocorticoid in treatment of systemic lupus erythematosus (SLE) have been the focus of debate, and our preliminary study indicates that ginsenosides can enhance the efficacy of dexamethasone. Objective: To observe the effects of ginsenosides combined with prednisone in SLE patients. Design, setting, participants and interventions: A total of 60 SLE patients from Department of Rheumatology and Immunology, Changhai Hospital, Second Military Medical University, were randomly divided into treatment group and control group, with 30 patients in each group. Patients in the treatment group were given routine treatment with prednisone plus ginsenosides, while those in the control group were given routine treatment with prednisone plus placebo. They were all treated for 3 months. Main outcome measures: After three-month treatment, syndrome score in traditional Chinese medicine (TCM), total response rate and symptom improvement rate were measured and evaluated. Results: Twenty-eight cases in treatment group and twenty-seven cases in control group were included in analysis. The total response rates in the treatment group and control group were 89.28% and 66.67% respectively, and there was a significant difference between the two groups (P<0.05). After treatment, the TCM syndrome scores in the two groups were lower than those before treatment (P<0.01), and prednisone plus ginsenosides was better in decreasing the TCM syndrome score than prednisone plus placebo (P<0.05). The symptoms were improved in the treatment group as compared with the control group (P<0.05). Conclusion: Prednisone combined with ginsenosides can increase the clinical effective rate and improve the clinical symptoms of SLE patients.

BackgroundDiabetes distress is highly prevalent and has adverse impacts in adolescent patients with type 1 diabetes. However， the related factors of diabetes distress in adolescents with type 1 diabetes are not clear. ObjectiveTo identify the factors associated with diabetes distress in adolescents with type 1 diabetes using Meta-analysis， and to provide a scientific evidence for effective prevention and improvement of diabetes distress in adolescents with type 1 diabetes. MethodsOn December 1， 2022， a computerized search was conducted on databases including PubMed， Cochrane Library， Web of Science， Embase， CNKI， Wanfang Data， VIP and China Biomedical Literature Database， and studies relevant to diabetes distress in adolescents with type 1 diabetes were systematically included. Quality assessment of cross-sectional and cohort studies was carried out using criteria defined by the Agency for Healthcare Research and Quality （AHRQ） and Newcastle-Ottawa Scale （NOS）. Then the included studies were pooled in a Meta-analysis using Revman 5.3. ResultsA total of 22 studies were included， involving 6 442 adolescents with type 1 diabetes. Meta-analysis denoted that the occurrence of diabetes distress among adolescents with type 1 diabetes was correlated with age （r=0.094，95% CI： 0.042~0.145）， HbA1c （r=0.291， 95% CI： 0.248~0.335）， trait anxiety （r=0.585， 95% CI： 0.526~0.639）， depressive symptoms （r=0.635， 95% CI： 0.590~0.676）， resilience （r=-0.410， 95% CI： -0.528~-0.276） and parents' diabetes distress （r=0.462， 95% CI： 0.421~0.501）. ConclusionFactors including age， HbA1c， trait anxiety， depressive symptoms， resilience and parents' diabetes distress are correlated with diabetes distress in adolescents with type 1 diabetes. ［Funded by Sichuan Science and Technology Program （number， 24KJPX0034）］

ObjectiveTo analyze the management and treatment for patients with severe mental disorders in Chengdu from 2016 to 2020， in order to provide references for the relevant authorities to formulate policies and improving the mental health service system. MethodsData relating to 22 districts （cities） and counties in Chengdu from January 1， 2016 to December 31， 2020 were extracted from the National Information System for Severe Mental Disorders. Indicators such as reported prevalence rate， management rate， standardized management rate， medication rate， regular medication rate and stable condition rate of patients with severe mental disorders were analyzed on a yearly basis. ResultsBy the end of 2020， there were 71 899 registered cases of severe mental disorders in Chengdu， with a reported prevalence rate of 0.34%， a standardized management rate of 95.53%， and a regular medication rate of 72.50%. From 2016 to 2020， except the reported prevalence rate （χ²=269.566， P<0.01）， management rate （χ²=384.030， P<0.01）， standardized management rate （χ²=309.742， P<0.01）， medication rate （χ²=414.252， P<0.01）， regular medication rate （χ²=316.172， P<0.01） and stable condition rate （χ²=288.335， P<0.01） had linear trends of increasing with the annual increase. ConclusionFrom 2016 to 2020， the management rate， treatment rate and regular medication rate of patients with severe mental disorders have been increased year by year in Chengdu. Nevertheless， the increase in reported prevalence rate should be accompanied by strengthened management and follow-up to increase the regular medication rate to maintain the stability of patients' conditions.